Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 2
2004 2
2005 3
2006 7
2007 8
2008 6
2009 6
2010 6
2011 6
2012 12
2013 18
2014 21
2015 21
2016 22
2017 22
2018 26
2019 32
2020 29
2021 33
2022 20
2023 16
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
PD-L1 as a Urine Biomarker in Renal Cell Carcinoma-A Case Series and Proof-of-Concept Study.
Reimold P, Tosev G, Kaczorowski A, Friedhoff J, Schwab C, Schütz V, Görtz M, Panzer N, Heller M, Aksoy C, Himmelsbach R, Walle T, Zschäbitz S, Jäger D, Duensing A, Stenzinger A, Hohenfellner M, Duensing S. Reimold P, et al. Among authors: jager d. Diagnostics (Basel). 2024 Mar 30;14(7):741. doi: 10.3390/diagnostics14070741. Diagnostics (Basel). 2024. PMID: 38611655 Free PMC article.
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications.
Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Zörnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, Jäger D, Podar K. Bashari MH, et al. Among authors: jager d. Breast Cancer Res. 2024 Apr 2;26(1):58. doi: 10.1186/s13058-024-01811-y. Breast Cancer Res. 2024. PMID: 38566222 Free PMC article. No abstract available.
Durvalumab Plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer: An Exploratory Analysis of Real-World Data.
Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, Longerich T, Mehrabi A, Chang DH, Liermann J, Schäfer S, Pfeiffenberger J, Jäger D, Michl P, Springfeld C, Dill MT. Olkus A, et al. Among authors: jager d. Target Oncol. 2024 Mar;19(2):213-221. doi: 10.1007/s11523-024-01044-1. Epub 2024 Feb 28. Target Oncol. 2024. PMID: 38416377 Free PMC article.
Primary Tumor Resection Before Systemic Therapy in Patients With Colon Cancer and Unresectable Metastases: Combined Results of the SYNCHRONOUS and CCRe-IV Trials.
Rahbari NN, Biondo S, Frago R, Feißt M, Kreisler E, Rossion I, Serrano M, Jäger D, Lehmann M, Sommer F, Dignass A, Bolling C, Vogel I, Bork U, Büchler MW, Folprecht G, Kieser M, Lordick F, Weitz J; SYNCHRONOUS and CCRe-IV Trial Groups. Rahbari NN, et al. Among authors: jager d. J Clin Oncol. 2024 May 1;42(13):1531-1541. doi: 10.1200/JCO.23.01540. Epub 2024 Feb 27. J Clin Oncol. 2024. PMID: 38412408 Clinical Trial.
MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection.
Meyer M, Parpoulas C, Barthélémy T, Becker JP, Charoentong P, Lyu Y, Börsig S, Bulbuc N, Tessmer C, Weinacht L, Ibberson D, Schmidt P, Pipkorn R, Eichmüller SB, Steinberger P, Lindner K, Poschke I, Platten M, Fröhling S, Riemer AB, Hassel JC, Roberti MP, Jäger D, Zörnig I, Momburg F. Meyer M, et al. Among authors: jager d. Front Immunol. 2024 Jan 4;14:1294565. doi: 10.3389/fimmu.2023.1294565. eCollection 2023. Front Immunol. 2024. PMID: 38239352 Free PMC article.
Long-Term Survival of Patients with Stage T1N0M1 Renal Cell Carcinoma.
Schütz V, Lin H, Kaczorowski A, Zschäbitz S, Jäger D, Stenzinger A, Duensing A, Debus J, Hohenfellner M, Duensing S. Schütz V, et al. Among authors: jager d. Cancers (Basel). 2023 Dec 6;15(24):5715. doi: 10.3390/cancers15245715. Cancers (Basel). 2023. PMID: 38136261 Free PMC article.
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Hohmann N, Sprick MR, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A, Springfeld C. Hohmann N, et al. Among authors: jager d. Clin Transl Sci. 2023 Dec;16(12):2483-2493. doi: 10.1111/cts.13661. Epub 2023 Nov 3. Clin Transl Sci. 2023. PMID: 37920921 Free PMC article.
Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.
Scherr AL, Nader L, Xu K, Elssner C, Ridder DA, Nichetti F, Mastel M, Fritzsche S, Kelmendi E, Schmitt N, Hoffmeister-Wittmann P, Weiler SME, Korell F, Albrecht T, Schwab M, Isele H, Kessler A, Hüllein J, Seretny A, Ye L, Urbanik T, Welte S, Leblond AL, Heilig CE, Rahbari M, Ali A, Gallage S, Lenoir B, Wilhelm N, Gärtner U, Ogrodnik SJ, Springfeld C, Tschaharganeh D, Fröhling S, Longerich T, Schulze-Bergkamen H, Jäger D, Brandl L, Schirmacher P, Straub BK, Weber A, De Toni EN, Goeppert B, Heikenwalder M, Jackstadt R, Roessler S, Breuhahn K, Köhler BC. Scherr AL, et al. Among authors: jager d. Hepatology. 2023 Nov 2. doi: 10.1097/HEP.0000000000000657. Online ahead of print. Hepatology. 2023. PMID: 37916976
Digital Spatial Profiling Identifies the Tumor Periphery as a Highly Active Biological Niche in Clear Cell Renal Cell Carcinoma.
Schneider F, Kaczorowski A, Jurcic C, Kirchner M, Schwab C, Schütz V, Görtz M, Zschäbitz S, Jäger D, Stenzinger A, Hohenfellner M, Duensing S, Duensing A. Schneider F, et al. Among authors: jager d. Cancers (Basel). 2023 Oct 19;15(20):5050. doi: 10.3390/cancers15205050. Cancers (Basel). 2023. PMID: 37894418 Free PMC article.
290 results